OPN-6602

December 9, 2024 Poster

OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

AUTHORS Matusow, et al
Programs OPN-6602

April 7, 2024 Poster

OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC

AUTHORS Matusow, et al
Programs OPN-6602

October 14, 2023 Poster

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

AUTHORS Matusow, et al
Programs OPN-6602